Heart device company to become publicly traded, aiming to raise $155 million
Kestra Medical Technologies, based in Washington, is making headlines as it prepares to go public on the Nasdaq Global Select Market. The company, known for its innovative wearable heart monitors and defibrillators, is set to trade under the ticker symbol KMTS. In this anticipated move, Kestra plans to offer 10 million common shares with an expected price range of $14 to $16 per share. Additionally, underwriters have the option to provide an extra 1.5 million common shares if needed. With this initial public offering, Kestra aims to raise between $133 million and $155 million, which it plans to allocate towards expanding its workforce by hiring new sales representatives and clinical care specialists. The company also intends to focus on enhancing its supply chain and revenue cycle management capabilities with the generated funds.
Leading financial institutions such as BofA Securities, Goldman Sachs, and Piper Sandler are spearheading the offering as lead bookrunners, while Wells Fargo Securities and Stifel are serving as bookrunners. Wolfe|Nomura Alliance has been appointed as the co-manager for this significant financial event for Kestra Medical Technologies.
A key product in Kestra’s lineup is the Assure wearable cardioverter defibrillator (WCD), a revolutionary vest-like system designed to protect individuals from sudden cardiac arrest. Describing their mission, Kestra emphasized their focus on utilizing innovative monitoring and therapeutic intervention technologies to revolutionize patient outcomes in cardiovascular disease. The company’s filing with the U.S. Securities and Exchange Commission highlighted the Assure WCD’s “significant clinical and functional advantages.” With more than 17,000 heart patients already benefitting from the device as of January 31, Kestra has made notable strides in transforming cardiovascular care.
The approval of the Assure WCD by the Food and Drug Administration (FDA) in July 2021 marked a significant milestone in the wearable heart device market. Prior to this, the market was limited to a single solution, but with the introduction of the Assure WCD, opportunities for patient care and protection expanded. Kestra’s impact on the market is evident in the growth of global WCD revenues to $1.3 billion in 2023, with a substantial portion of revenues originating in the U.S. This growth trajectory underscores the importance and potential of wearable cardiac devices in improving patient outcomes and reducing risks of sudden cardiac events.
With notable backers such as Andera Partners, Ally Bridge Group, Longitude Capital, and Omega Funds leading the investment charge in July 2024, Kestra received a significant funding boost of $196 million. This funding round, supported by key investors such as Bain Capital and Endeavour Vision, reflects the confidence in Kestra’s innovative approach to cardiovascular care and its potential to make a lasting impact in the field.
In conclusion, Kestra Medical Technologies’ upcoming public offering underscores the company’s commitment to revolutionizing cardiovascular care through cutting-edge wearable heart monitors and defibrillators. With a focus on patient outcomes and technological innovation, Kestra is poised to make significant strides in the cardiovascular healthcare market and improve the lives of individuals at risk of sudden cardiac events.